Safety, Tolerability, and Pharmacokinetics of Posaconazole Oral Suspension in Neutropenic Children

A. Arrieta, L. Sung, F. Berthold, A. H. Groll, T. Lehrnbecher, J. Bradley, C. M. Zwaan, J. Li, H. Waskin, M. Walker, N. Kartsonis, A. Paschke, T. J. Walsh

Author address: 

Pediatric Posaconazole Study Group, Whitehouse Station, NJ; Merck, Whitehouse Station, NJ.


Background: Posaconazole (POS) is a potent triazole antifungal agent approved in adults for treatment and prophylaxis of invasive fungal infections (IFI). Pharmacokinetic (PK) data are limited for the pediatric population, and thus, dosing is uncertain. In this first clinical trial of POS in pediatric patients, the objective was to evaluate the PK, safety and tolerability of POS oral suspension in children aged 3 months-

abstract No: 


Full conference title: 

53rd Interscience Conference on Antimicrobial Agents and Chemotherapy
    • ICAAC, 53rd (2013)